scholarly journals Generation of Red Blood Cells from Human Induced Pluripotent Stem Cells

2011 ◽  
Vol 20 (9) ◽  
pp. 1639-1647 ◽  
Author(s):  
Jessica Dias ◽  
Marina Gumenyuk ◽  
HyunJun Kang ◽  
Maxim Vodyanik ◽  
Junying Yu ◽  
...  
Keyword(s):  
Stem Cells ◽  
Red Blood Cells ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Blood Cells ◽  
Induced Pluripotent

Dna methylation of manufactured red blood cells from human induced pluripotent stem cells

2017 ◽  
Vol 53 ◽  
pp. S111-S112
Author(s):  
Isabel Dorn ◽  
Claudia Bernecker ◽  
Slave Trajanoski ◽  
Holm Zaehres ◽  
Peter Schlenke ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Stem Cells ◽  
Red Blood Cells ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Blood Cells ◽  
Induced Pluripotent

Generation of human induced pluripotent stem cells from a Bombay individual: Moving towards “universal-donor” red blood cells

2010 ◽  
Vol 391 (1) ◽  
pp. 329-334 ◽  
Author(s):  
Ali Seifinejad ◽  
Adeleh Taei ◽  
Mehdi Totonchi ◽  
Hamed Vazirinasab ◽  
Seideh Nafiseh Hassani ◽  
...  
Keyword(s):  
Stem Cells ◽  
Red Blood Cells ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Blood Cells ◽  
Induced Pluripotent ◽  
Universal Donor

scholarly journals PSC-RED, an Albumin-Free Robust Erythroid Differentiation Method to Produce Enucleated Red Blood Cells from Human Pluripotent Stem Cells

2019 ◽  
Author(s):  
Emmanuel N Olivier ◽  
Shouping Zhang ◽  
Zi Yan ◽  
Sandra Suzuka ◽  
Karl Roberts ◽  
...  
Keyword(s):  
Stem Cells ◽  
Red Blood Cells ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Blood Cells ◽  
Erythroid Differentiation ◽  
Economic Viability ◽  
List Type ◽  
Potential Applications ◽  
Induced Pluripotent

AbstractCultured red blood cells (cRBCs) have many potential applications in transfusion medicine and drug delivery. We report that we have developed chemically defined, albumin-free Robust Erythroid Differentiation (RED) methods to produce enucleated cRBCs from human induced pluripotent stem cells (iPSCs). Human iPSC-derived cRBCs produced with either the short or long variation of the RED protocol respectively express embryonic/fetal or a mixture of fetal and adult hemoglobins. The long version of the protocol produces up to 50% of enucleated cells at an unprecedented yield. RED is scalable and relies on inexpensive components and therefore dramatically increases the feasibility and economic viability of all translational applications of cRBCs.HighlightsPSC-RED: A chemically-defined, albumin-free Robust Erythroid Differentiation (RED) methods to produce cRBCs from human induced pluripotent stem cells.PSC-RED produces up to 50% enucleated cells at an unprecedented yield.PSC-RED is scalable and relies on inexpensive components and therefore increases the feasibility and economic viability of translational applications of cRBCs.

scholarly journals Production of Embryonic and Fetal-Like Red Blood Cells from Human Induced Pluripotent Stem Cells

PLoS ONE ◽  
2011 ◽  
Vol 6 (10) ◽  
pp. e25761 ◽  
Author(s):  
Chan-Jung Chang ◽  
Koyel Mitra ◽  
Mariko Koya ◽  
Michelle Velho ◽  
Romain Desprat ◽  
...  
Keyword(s):  
Stem Cells ◽  
Red Blood Cells ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Blood Cells ◽  
Induced Pluripotent

scholarly journals Umbilical Cord Tissue as a Source of Young Cells for the Derivation of Induced Pluripotent Stem Cells Using Non-Integrating Episomal Vectors and Feeder-Free Conditions

Cells ◽  
2020 ◽  
Vol 10 (1) ◽  
pp. 49
Author(s):  
Aisha Mohamed ◽  
Theresa Chow ◽  
Jennifer Whiteley ◽  
Amanda Fantin ◽  
Kersti Sorra ◽  
...  
Keyword(s):  
Stem Cells ◽  
Induced Pluripotent Stem Cells ◽  
Umbilical Cord ◽  
Pluripotent Stem Cells ◽  
Blood Cells ◽  
Growth Media ◽  
Donor Cells ◽  
Episomal Vectors ◽  
Umbilical Cord Tissue ◽  
Induced Pluripotent

The clinical application of induced pluripotent stem cells (iPSC) needs to balance the use of an autologous source that would be a perfect match for the patient against any safety or efficacy issues that might arise with using cells from an older patient or donor. Drs. Takahashi and Yamanaka and the Office of Cellular and Tissue-based Products (PMDA), Japan, have had concerns over the existence of accumulated DNA mutations in the cells of older donors and the possibility of long-term negative effects. To mitigate the risk, they have chosen to partner with the Umbilical Cord (UC) banks in Japan to source allogeneic-matched donor cells. Production of iPSCs from UC blood cells (UCB) has been successful; however, reprogramming blood cells requires cell enrichment with columns or flow cytometry and specialized growth media. These requirements add to the cost of production and increase the manipulation of the cells, which complicates the regulatory approval process. Alternatively, umbilical cord tissue mesenchymal stromal cells (CT-MSCs) have the same advantage as UCB cells of being a source of young donor cells. Crucially, CT-MSCs are easier and less expensive to harvest and grow compared to UCB cells. Here, we demonstrate that CT-MSCs can be easily isolated without expensive enzymatic treatment or columns and reprogramed well using episomal vectors, which allow for the removal of the reprogramming factors after a few passages. Together the data indicates that CT-MSCs are a viable source of donor cells for the production of clinical-grade, patient matched iPSCs.

Sign in / Sign up

Export Citation Format

Share Document